Cargando…
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
AIMS: Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary arter...
Autores principales: | Goto, Shinya, Ogawa, Hisao, Takeuchi, Masaru, Flather, Marcus D., Bhatt, Deepak L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966970/ https://www.ncbi.nlm.nih.gov/pubmed/20805115 http://dx.doi.org/10.1093/eurheartj/ehq320 |
Ejemplares similares
-
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012) -
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010) -
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011) -
Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac
surgery without atrial ablation in patients with coronary and/or valvular heart disease
plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre
study(†)
por: Budera, Petr, et al.
Publicado: (2012) -
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)